Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This protocol will evaluate Tacrolimus and MMF after conditioning with fludarabine and
low-dose TBI in patients who are not candidates for conventional allografting. A novel
approach to immunosuppression will be tested incorporating an early but extended taper of
Tacrolimus starting on day +80 or in the case of relapse. The goal is to induce early
immunity and GVT effects without compromising GVHD control. The anti-metabolite MMF will be
re-introduced on day +100 to try and induce tolerance and block chronic GVHD during the taper
of the Tacrolimus. DLI may be given in the presence of disease progression but not for mixed
chimerism as in previous protocols.